TG Therapeutics, Inc. $TGTX Stock Holdings Decreased by WINTON GROUP Ltd

WINTON GROUP Ltd reduced its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 79.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 25,242 shares of the biopharmaceutical company’s stock after selling 99,758 shares during the quarter. WINTON GROUP Ltd’s holdings in TG Therapeutics were worth $752,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Danske Bank A S purchased a new position in shares of TG Therapeutics in the third quarter worth approximately $25,000. Optiver Holding B.V. grew its position in TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares in the last quarter. Bessemer Group Inc. grew its position in TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares in the last quarter. Hantz Financial Services Inc. grew its position in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 573 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

Shares of TGTX opened at $46.62 on Thursday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The company has a market capitalization of $7.14 billion, a PE ratio of 16.30 and a beta of 1.68. The company’s 50 day moving average price is $37.76 and its 200 day moving average price is $32.88. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $49.31.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The business had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. TG Therapeutics’s revenue was up 69.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.03 earnings per share. Research analysts expect that TG Therapeutics, Inc. will post 1.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on TGTX shares. Weiss Ratings raised shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of TG Therapeutics in a research report on Wednesday, May 27th. Zacks Research raised shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $52.50.

More TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: TG Therapeutics reported positive topline Phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis, with 82% of subjects achieving a clinically meaningful improvement and a mean improvement of more than 4 points in MG-ADL; the company also said it is starting a randomized Phase 2 study. Article Title
• Positive Sentiment: Investors are reacting to early data suggesting at-home subcutaneous BRIUMVI could expand the drug’s use into additional indications and potentially increase the product’s commercial upside. Article Title
• Positive Sentiment: Options activity surged sharply, with traders buying far more call options than normal, signaling speculative bullish sentiment around the stock. Article Title
• Neutral Sentiment: TG Therapeutics also presented at Goldman Sachs’ healthcare conference, which keeps the company in front of investors but did not appear to be the main catalyst for the move. Article Title
• Negative Sentiment: No major negative company-specific headlines were reported in the latest set of articles; the only potential risk is that the new BRIUMVI data are still early-stage and will need confirmation in later trials.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.